MedTrace Logo

The Efficacy of N-acetyl-cysteine in the Treatment of Burning Mouth Syndrome

NCT05309070 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2025-05-14

No results posted yet for this study

Summary

The purpose of this study was to examine the efficacy of N-acetyl cysteine in the treatment of burning mouth syndrome. A control group of patients with burning mouth syndrome will receive a placebo. The effect of the therapy will be monitored with the help of the visual-analogue scale (VAS) and the oral health-related quality of life questionnaire (OHIP-14).

Conditions

  • Burning Mouth Syndrome

Interventions

DIETARY_SUPPLEMENT

N-acetyl cysteine

Study group will receive N-acetyl cysteine in unmarked boxes, in a daily dose of 1200 mg during two months

OTHER

placebo

Control group will receive a placebo, in unmarked boxes, during two months

Sponsors & Collaborators

  • University of Zagreb

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-01
Primary Completion
2025-02-28
Completion
2025-02-28

Countries

  • Croatia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05309070 on ClinicalTrials.gov